Incidence of Postmolar Gestational Trophoblastic Disease in Androgenetic Moles and the Morphological Features Associated with Low Risk Postmolar Gestational Trophoblastic Disease

Overview

Journal Cancer Sci

Specialty Oncology

Date 2010 Jun 4

PMID 20518791

Citations 10

Authors

Eisuke Kaneki

Hiroaki Kobayashi

Toshio Hirakawa

Takao Matsuda

Hidenori Kato

Norio Wake

Affiliations

Soon will be listed here.

Abstract

In the present study, we evaluated the incidence of postmolar gestational trophoblastic disease (GTD) in molar pregnancy. We also validated the macroscopic diagnosis based on the Japan Society of Obstetrics and Gynecology (JSOG) classification. A total of 297 samples of hydropic villi were classified according to DNA polymorphisms as androgenetic moles, dispermic triploids, or biparental diploids (hydropic abortion), clinically corresponding to complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), and hydropic abortion, respectively. These samples were also classified morphologically based on the JSOG classification. A follow-up study was performed to investigate the incidence of postmolar GTD. A subset of 267 samples eligible for testing were analyzed and diagnosed as androgenetic moles (232 cases), dispermic triploids (20 cases), and biparental diploids (15 cases). Most of the macroscopically diagnosed CHM cases were genetically androgenetic in origin. The PHM cases consisted of 30 androgenetic moles and 12 dispermic triploids. We reviewed the outcomes of 200 patients (178 cases of androgenetic mole, 13 cases of dispermic triploids, and nine cases of biparental diploids). Twenty-eight cases (16%) of androgenetic moles developed postmolar GTD. None of the patients with dispermic triploids developed postmolar GTD. Among the 28 patients who developed postmolar GTD, the shortest diameter of the largest hydropic villi was significantly longer than that of patients not developing postmolar GTD. None of the patients with androgenetic moles who had hydropic villi <2 mm in their shortest diameter developed postmolar GTD. For the patients with dispermic triploids, the risk of postmolar GTD is extremely low. The risk of postmolar GTD is also low in patients with androgenetic moles with small hydropic villi. The JSOG classification based on the morphology of hydropic villi is reliable for the diagnosis of CHM, but inaccurate for the diagnosis of PHM or "microscopic" moles.

Citing Articles

The effect of prophylactic chemotherapy on treatment outcome of postmolar gestational trophoblastic neoplasia.

Liu Y, Ye Y, Cheng X, Lu W, Xie X, Wang X BMC Womens Health. 2023; 23(1):1.

PMID: 36593459 PMC: 9806869. DOI: 10.1186/s12905-022-02134-w.

Epidemiologic study on gestational trophoblastic diseases in Japan.

Yamamoto E, Nishino K, Niimi K, Ino K J Gynecol Oncol. 2022; 33(6):e72.

PMID: 36047375 PMC: 9634103. DOI: 10.3802/jgo.2022.33.e72.

PADI6 Regulates Trophoblast Cell Migration-Invasion Through the Hippo/YAP1 Pathway in Hydatidiform Moles.

Huang B, Zhao Y, Zhou L, Gong T, Feng J, Han P J Inflamm Res. 2021; 14:3489-3500.

PMID: 34326657 PMC: 8314932. DOI: 10.2147/JIR.S313422.

The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study.

Yamamoto E, Trinh T, Sekiya Y, Tamakoshi K, Nguyen X, Nishino K Nagoya J Med Sci. 2020; 82(2):183-191.

PMID: 32581399 PMC: 7276412. DOI: 10.18999/nagjms.82.2.183.

MiR-30a-5p inhibits proliferation and metastasis of hydatidiform mole by regulating B3GNT5 through ERK/AKT pathways.

Guo Z, Sun Q, Liao Y, Liu C, Zhao W, Li X J Cell Mol Med. 2020; 24(15):8350-8362.

PMID: 32575164 PMC: 7412694. DOI: 10.1111/jcmm.15247.

References

Mungan T, Kuscu E, Dabakoglu T, Senoz S, Ugur M, Cobanoglu O . Hydatidiform mole: clinical analysis of 310 patients. Int J Gynaecol Obstet. 1996; 52(3):233-6. DOI: 10.1016/0020-7292(95)02608-8. View

Jun S, Ro J, Kim K . p57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathology. 2003; 43(1):17-25. DOI: 10.1046/j.1365-2559.2003.01667.x. View

Genest D . Partial hydatidiform mole: clinicopathological features, differential diagnosis, ploidy and molecular studies, and gold standards for diagnosis. Int J Gynecol Pathol. 2001; 20(4):315-22. DOI: 10.1097/00004347-200110000-00001. View

Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Seki K, Sekiya S . Changes in the incidence of molar pregnancies. A population-based study in Chiba Prefecture and Japan between 1974 and 2000. Hum Reprod. 2003; 18(1):172-5. DOI: 10.1093/humrep/deg008. View

Jacobs P, Angell R, Buchanan I, Hassold T, Matsuyama A, Manuel B . The origin of human triploids. Ann Hum Genet. 1978; 42(1):49-57. DOI: 10.1111/j.1469-1809.1978.tb00930.x. View

Kajii T, Ohama K . Androgenetic origin of hydatidiform mole. Nature. 1977; 268(5621):633-4. DOI: 10.1038/268633a0. View

Kato H, Matsuda T, Hirakawa T, Ueda K, Inoue T, Miyanari Y . Differential diagnosis between complete and partial mole by TSSC3 antibody completely correlates to DNA diagnosis. Diagn Mol Pathol. 2005; 14(3):164-9. DOI: 10.1097/01.pas.0000162757.91649.a3. View

Ayhan A, Tuncer Z, Halilzade H, Kucukali T . Predictors of persistent disease in women with complete hydatidiform mole. J Reprod Med. 1996; 41(8):591-4. View

LAWLER S, Pickthall V, Fisher R, Povey S, Evans M, Szulman A . Genetic studies of complete and partial hydatidiform moles. Lancet. 1979; 2(8142):580. DOI: 10.1016/s0140-6736(79)91632-5. View

10.

Paradinas F, Browne P, Fisher R, Foskett M, Bagshawe K, NEWLANDS E . A clinical, histopathological and flow cytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathology. 1996; 28(2):101-10. DOI: 10.1046/j.1365-2559.1996.247295.x. View

11.

Niemann I, Petersen L, Hansen E, Sunde L . Predictors of low risk of persistent trophoblastic disease in molar pregnancies. Obstet Gynecol. 2006; 107(5):1006-11. DOI: 10.1097/01.AOG.0000210635.24543.3b. View

12.

Wake N, Takagi N, Sasaki M . Androgenesis as a cause of hydatidiform mole. J Natl Cancer Inst. 1978; 60(1):51-7. DOI: 10.1093/jnci/60.1.51. View

13.

Morrow C . Postmolar trophoblastic disease: diagnosis, management, and prognosis. Clin Obstet Gynecol. 1984; 27(1):211-20. DOI: 10.1097/00003081-198403000-00028. View

14.

Goto S, Yamada A, Ishizuka T, Tomoda Y . Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol. 1993; 48(2):165-70. DOI: 10.1006/gyno.1993.1028. View

15.

Berkowitz R, Goldstein D . Chorionic tumors. N Engl J Med. 1996; 335(23):1740-8. DOI: 10.1056/NEJM199612053352306. View

16.

Felemban A, Bakri Y, Alkharif H, Altuwaijri S, Shalhoub J, Berkowitz R . Complete molar pregnancy. Clinical trends at King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia. J Reprod Med. 1998; 43(1):11-3. View

17.

Niemann I, Hansen E, Sunde L . The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol. 2006; 104(2):411-5. DOI: 10.1016/j.ygyno.2006.08.025. View

18.

Rice L, Berkowitz R, Lage J, Goldstein D, Bernstein M . Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol. 1990; 36(3):358-62. DOI: 10.1016/0090-8258(90)90142-8. View

19.

Curry S, Hammond C, Tyrey L, Creasman W, Parker R . Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstet Gynecol. 1975; 45(1):1-8. View

20.

Lage J, Mark S, Roberts D, Goldstein D, Bernstein M, Berkowitz R . A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol. 1992; 79(3):403-10. DOI: 10.1097/00006250-199203000-00016. View